Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks under $100. On October 9, BofA raised the firm’s price target on Teva to$24 from $22, while keeping a Buy rating on the shares. This sentiment was posted as BofA analyzed Q3 2025 drug pricing & sales volume and company comments, and concluded that the firm anticipates no significant Q3 EPS surprises (beats or misses) and no changes to 2026 financial outlooks for the biopharma companies that it covers. Earlier in Q2 202 ...